Market Closed -
Nyse
04:00:02 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
103.2
USD
|
-0.58%
|
|
-4.60%
|
+2.39%
|
Fiscal Period: Junio |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
14,039
|
15,239
|
16,565
|
14,240
|
24,078
|
25,104
|
-
|
-
|
Enterprise Value (EV)
1 |
19,539
|
19,243
|
19,394
|
14,838
|
24,736
|
24,668
|
23,761
|
23,438
|
P/E ratio
|
10.4
x
|
-4.14
x
|
27.4
x
|
-15.6
x
|
94.6
x
|
18
x
|
15.4
x
|
14
x
|
Yield
|
4.06%
|
3.7%
|
3.41%
|
3.75%
|
2.1%
|
1.96%
|
2%
|
2.06%
|
Capitalization / Revenue
|
0.1
x
|
0.1
x
|
0.1
x
|
0.08
x
|
0.12
x
|
0.11
x
|
0.11
x
|
0.1
x
|
EV / Revenue
|
0.13
x
|
0.13
x
|
0.12
x
|
0.08
x
|
0.12
x
|
0.11
x
|
0.1
x
|
0.09
x
|
EV / EBITDA
|
7.15
x
|
6.94
x
|
7.5
x
|
6.29
x
|
10
x
|
8.67
x
|
7.61
x
|
7.03
x
|
EV / FCF
|
8.16
x
|
12.1
x
|
9.56
x
|
5.43
x
|
10.5
x
|
11.6
x
|
11.8
x
|
10.8
x
|
FCF Yield
|
12.3%
|
8.24%
|
10.5%
|
18.4%
|
9.53%
|
8.63%
|
8.47%
|
9.23%
|
Price to Book
|
1.63
x
|
8.55
x
|
9.29
x
|
-20.6
x
|
-8.32
x
|
-8.33
x
|
-10.4
x
|
-29.6
x
|
Nbr of stocks (in thousands)
|
298,060
|
291,986
|
290,148
|
272,427
|
254,600
|
243,233
|
-
|
-
|
Reference price
2 |
47.10
|
52.19
|
57.09
|
52.27
|
94.57
|
103.2
|
103.2
|
103.2
|
Announcement Date
|
8/8/19
|
8/6/20
|
8/5/21
|
8/11/22
|
8/15/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
145,534
|
152,922
|
162,467
|
181,364
|
205,012
|
225,164
|
238,097
|
254,928
|
EBITDA
1 |
2,732
|
2,773
|
2,587
|
2,358
|
2,464
|
2,845
|
3,124
|
3,334
|
EBIT
1 |
2,353
|
2,384
|
2,255
|
1,990
|
2,057
|
2,386
|
2,599
|
2,768
|
Operating Margin
|
1.62%
|
1.56%
|
1.39%
|
1.1%
|
1%
|
1.06%
|
1.09%
|
1.09%
|
Earnings before Tax (EBT)
1 |
1,751
|
-3,772
|
323
|
-769
|
638
|
1,536
|
2,115
|
2,290
|
Net income
1 |
1,363
|
-3,696
|
611
|
-933
|
261
|
1,210
|
1,545
|
1,689
|
Net margin
|
0.94%
|
-2.42%
|
0.38%
|
-0.51%
|
0.13%
|
0.54%
|
0.65%
|
0.66%
|
EPS
2 |
4.530
|
-12.61
|
2.080
|
-3.350
|
1.000
|
5.723
|
6.696
|
7.362
|
Free Cash Flow
1 |
2,394
|
1,585
|
2,029
|
2,735
|
2,358
|
2,128
|
2,012
|
2,163
|
FCF margin
|
1.64%
|
1.04%
|
1.25%
|
1.51%
|
1.15%
|
0.95%
|
0.85%
|
0.85%
|
FCF Conversion (EBITDA)
|
87.63%
|
57.16%
|
78.43%
|
115.99%
|
95.7%
|
74.81%
|
64.42%
|
64.88%
|
FCF Conversion (Net income)
|
175.64%
|
-
|
332.08%
|
-
|
903.45%
|
175.86%
|
130.27%
|
128.06%
|
Dividend per Share
2 |
1.910
|
1.929
|
1.948
|
1.960
|
1.988
|
2.025
|
2.061
|
2.125
|
Announcement Date
|
8/8/19
|
8/6/20
|
8/5/21
|
8/11/22
|
8/15/23
|
-
|
-
|
-
|
Fiscal Period: June |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
---|
Net sales
1 |
43,968
|
45,457
|
44,836
|
47,103
|
49,603
|
51,469
|
50,487
|
53,453
|
54,763
|
57,445
|
56,103
|
57,754
|
58,050
|
60,685
|
59,036
|
EBITDA
1 |
616
|
552
|
647
|
542
|
523
|
566
|
707
|
667
|
679
|
674
|
765.5
|
732.4
|
719.3
|
752.1
|
844.9
|
EBIT
1 |
527
|
467
|
545
|
450
|
423
|
467
|
606
|
560
|
571
|
562
|
651.7
|
620.6
|
606.1
|
636.2
|
716.9
|
Operating Margin
|
1.2%
|
1.03%
|
1.22%
|
0.96%
|
0.85%
|
0.91%
|
1.2%
|
1.05%
|
1.04%
|
0.98%
|
1.16%
|
1.07%
|
1.04%
|
1.05%
|
1.21%
|
Earnings before Tax (EBT)
1 |
369
|
-973
|
-137
|
-28
|
110
|
-137
|
544
|
121
|
-26
|
490
|
600.2
|
482
|
604.9
|
647.3
|
762.6
|
Net income
1 |
271
|
49
|
-1,391
|
138
|
110
|
-130
|
345
|
-64
|
5
|
353
|
477.9
|
369.5
|
395
|
415
|
472.2
|
Net margin
|
0.62%
|
0.11%
|
-3.1%
|
0.29%
|
0.22%
|
-0.25%
|
0.68%
|
-0.12%
|
0.01%
|
0.61%
|
0.85%
|
0.64%
|
0.68%
|
0.68%
|
0.8%
|
EPS
2 |
0.9400
|
0.1700
|
-5.050
|
0.5000
|
0.4000
|
-0.5000
|
1.340
|
-0.2500
|
0.0200
|
1.430
|
1.930
|
1.582
|
1.620
|
1.698
|
1.928
|
Dividend per Share
2 |
0.4908
|
0.4908
|
0.4908
|
0.4908
|
0.4957
|
0.4957
|
0.4957
|
0.5006
|
0.5006
|
0.5006
|
0.5051
|
0.5069
|
0.5238
|
0.5257
|
0.5276
|
Announcement Date
|
11/9/21
|
2/3/22
|
5/5/22
|
8/11/22
|
11/4/22
|
2/2/23
|
5/4/23
|
8/15/23
|
11/3/23
|
2/1/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
5,500
|
4,004
|
2,829
|
598
|
658
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
436
|
1,343
|
1,666
|
Leverage (Debt/EBITDA)
|
2.013
x
|
1.444
x
|
1.094
x
|
0.2536
x
|
0.267
x
|
-
|
-
|
-
|
Free Cash Flow
1 |
2,394
|
1,585
|
2,029
|
2,735
|
2,358
|
2,128
|
2,012
|
2,163
|
ROE (net income / shareholders' equity)
|
25.7%
|
39.5%
|
91.3%
|
261%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
3.93%
|
3.93%
|
3.84%
|
3.21%
|
3.48%
|
3.7%
|
4.1%
|
4.15%
|
Assets
1 |
34,703
|
-94,103
|
15,904
|
-29,039
|
7,500
|
32,737
|
37,689
|
40,743
|
Book Value Per Share
2 |
28.90
|
6.110
|
6.140
|
-2.540
|
-11.40
|
-12.40
|
-9.900
|
-3.490
|
Cash Flow per Share
2 |
9.040
|
6.690
|
8.260
|
11.20
|
10.80
|
9.400
|
11.10
|
11.80
|
Capex
1 |
328
|
375
|
400
|
387
|
481
|
502
|
513
|
526
|
Capex / Sales
|
0.23%
|
0.25%
|
0.25%
|
0.21%
|
0.23%
|
0.22%
|
0.22%
|
0.21%
|
Announcement Date
|
8/8/19
|
8/6/20
|
8/5/21
|
8/11/22
|
8/15/23
|
-
|
-
|
-
|
Last Close Price
103.2
USD Average target price
112.4
USD Spread / Average Target +8.93% Consensus |
1st Jan change
|
Capi.
|
---|
| +2.39% | 25.1B | | +17.35% | 71.39B | | +5.38% | 8.59B | | +6.69% | 8.19B | | -20.96% | 7.91B | | +0.49% | 4.54B | | +17.12% | 4.31B | | -3.38% | 3.93B | | -2.61% | 3.86B | | +22.08% | 3.64B |
Pharmaceuticals Wholesale
|